Structural basis for the pathogenicity of parkin catalytic domain mutants

Mutations in the E3 ubiquitin ligase parkin cause a familial form of Parkinson’s disease. Parkin and the mitochondrial kinase PTEN-induced kinase 1 assure quality control of mitochondria through selective autophagy of mitochondria (mitophagy). Whereas numerous parkin mutations have been functionally...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of biological chemistry 2025-01, Vol.301 (1), p.108051, Article 108051
Hauptverfasser: Wagner, Julian P., Sauvé, Véronique, Saran, Anshu, Gehring, Kalle
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 1
container_start_page 108051
container_title The Journal of biological chemistry
container_volume 301
creator Wagner, Julian P.
Sauvé, Véronique
Saran, Anshu
Gehring, Kalle
description Mutations in the E3 ubiquitin ligase parkin cause a familial form of Parkinson’s disease. Parkin and the mitochondrial kinase PTEN-induced kinase 1 assure quality control of mitochondria through selective autophagy of mitochondria (mitophagy). Whereas numerous parkin mutations have been functionally and structurally characterized, several Parkinson’s disease mutations found in the catalytic Rcat domain of parkin remain poorly understood. Here, we characterize two pathogenic Rcat mutants, T415N and P437L. We demonstrate that both mutants exhibit impaired activity using autoubiquitination and ubiquitin vinyl sulfone assays. We determine the minimal ubiquitin-binding segment and show that both mutants display impaired binding of ubiquitin charged on the E2 enzyme. Finally, we use AlphaFold 3 to predict a model of the phospho-parkin:phospho-ubiquitin:ubiquitin-charged E2 complex. The model shows the repressor element of parkin and the N-terminal residues of the catalytic domain form a helix to position ubiquitin for transfer from the E2 to parkin. Our results rationalize the pathogenicity of the parkin mutations and deepen our understanding of the active parkin:E2∼Ub complex.
doi_str_mv 10.1016/j.jbc.2024.108051
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3146516862</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0021925824025535</els_id><sourcerecordid>3146516862</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1503-c91735a0e0c9b8fddfad151a5ca71ab2b570b67d624d703745c84d217be069f73</originalsourceid><addsrcrecordid>eNp9kE1LAzEQhoMotlZ_gBfZo5etmWST3cWTFD8KBQ8qeAvZJGuz7kdNskL_vSmtHp3LzLy888I8CF0CngMGftPMm0rNCSZZ3AvM4AhN40BTyuD9GE0xJpCWhBUTdOZ9g2NlJZyiCS05BV7SKVq-BDeqMDrZJpX01if14JKwNslGhvXwYXqrbNgmQx0F92n7RMkg222wKtFDJ6PQjUH2wZ-jk1q23lwc-gy9Pdy_Lp7S1fPjcnG3ShUwTFNVQk6ZxAarsipqrWupgYFkSuYgK1KxHFc815xkOsc0z5gqMk0grwzmZZ3TGbre527c8DUaH0RnvTJtK3szjF5QyDgDXnASrbC3Kjd470wtNs520m0FYLEjKBoRCYodQbEnGG-uDvFj1Rn9d_GLLBpu9wYTn_y2xgmvrOmV0dYZFYQe7D_xPzsqgOw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3146516862</pqid></control><display><type>article</type><title>Structural basis for the pathogenicity of parkin catalytic domain mutants</title><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Wagner, Julian P. ; Sauvé, Véronique ; Saran, Anshu ; Gehring, Kalle</creator><creatorcontrib>Wagner, Julian P. ; Sauvé, Véronique ; Saran, Anshu ; Gehring, Kalle</creatorcontrib><description>Mutations in the E3 ubiquitin ligase parkin cause a familial form of Parkinson’s disease. Parkin and the mitochondrial kinase PTEN-induced kinase 1 assure quality control of mitochondria through selective autophagy of mitochondria (mitophagy). Whereas numerous parkin mutations have been functionally and structurally characterized, several Parkinson’s disease mutations found in the catalytic Rcat domain of parkin remain poorly understood. Here, we characterize two pathogenic Rcat mutants, T415N and P437L. We demonstrate that both mutants exhibit impaired activity using autoubiquitination and ubiquitin vinyl sulfone assays. We determine the minimal ubiquitin-binding segment and show that both mutants display impaired binding of ubiquitin charged on the E2 enzyme. Finally, we use AlphaFold 3 to predict a model of the phospho-parkin:phospho-ubiquitin:ubiquitin-charged E2 complex. The model shows the repressor element of parkin and the N-terminal residues of the catalytic domain form a helix to position ubiquitin for transfer from the E2 to parkin. Our results rationalize the pathogenicity of the parkin mutations and deepen our understanding of the active parkin:E2∼Ub complex.</description><identifier>ISSN: 0021-9258</identifier><identifier>ISSN: 1083-351X</identifier><identifier>EISSN: 1083-351X</identifier><identifier>DOI: 10.1016/j.jbc.2024.108051</identifier><identifier>PMID: 39631693</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>AlphaFold ; E3 ubiquitin ligase ; parkin ; PRKN ; structural biology ; ubiquitin</subject><ispartof>The Journal of biological chemistry, 2025-01, Vol.301 (1), p.108051, Article 108051</ispartof><rights>2024 The Authors</rights><rights>Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c1503-c91735a0e0c9b8fddfad151a5ca71ab2b570b67d624d703745c84d217be069f73</cites><orcidid>0000-0001-6500-1184 ; 0009-0008-8905-1504 ; 0000-0002-5981-4573 ; 0000-0002-1232-4825</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39631693$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wagner, Julian P.</creatorcontrib><creatorcontrib>Sauvé, Véronique</creatorcontrib><creatorcontrib>Saran, Anshu</creatorcontrib><creatorcontrib>Gehring, Kalle</creatorcontrib><title>Structural basis for the pathogenicity of parkin catalytic domain mutants</title><title>The Journal of biological chemistry</title><addtitle>J Biol Chem</addtitle><description>Mutations in the E3 ubiquitin ligase parkin cause a familial form of Parkinson’s disease. Parkin and the mitochondrial kinase PTEN-induced kinase 1 assure quality control of mitochondria through selective autophagy of mitochondria (mitophagy). Whereas numerous parkin mutations have been functionally and structurally characterized, several Parkinson’s disease mutations found in the catalytic Rcat domain of parkin remain poorly understood. Here, we characterize two pathogenic Rcat mutants, T415N and P437L. We demonstrate that both mutants exhibit impaired activity using autoubiquitination and ubiquitin vinyl sulfone assays. We determine the minimal ubiquitin-binding segment and show that both mutants display impaired binding of ubiquitin charged on the E2 enzyme. Finally, we use AlphaFold 3 to predict a model of the phospho-parkin:phospho-ubiquitin:ubiquitin-charged E2 complex. The model shows the repressor element of parkin and the N-terminal residues of the catalytic domain form a helix to position ubiquitin for transfer from the E2 to parkin. Our results rationalize the pathogenicity of the parkin mutations and deepen our understanding of the active parkin:E2∼Ub complex.</description><subject>AlphaFold</subject><subject>E3 ubiquitin ligase</subject><subject>parkin</subject><subject>PRKN</subject><subject>structural biology</subject><subject>ubiquitin</subject><issn>0021-9258</issn><issn>1083-351X</issn><issn>1083-351X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2025</creationdate><recordtype>article</recordtype><recordid>eNp9kE1LAzEQhoMotlZ_gBfZo5etmWST3cWTFD8KBQ8qeAvZJGuz7kdNskL_vSmtHp3LzLy888I8CF0CngMGftPMm0rNCSZZ3AvM4AhN40BTyuD9GE0xJpCWhBUTdOZ9g2NlJZyiCS05BV7SKVq-BDeqMDrZJpX01if14JKwNslGhvXwYXqrbNgmQx0F92n7RMkg222wKtFDJ6PQjUH2wZ-jk1q23lwc-gy9Pdy_Lp7S1fPjcnG3ShUwTFNVQk6ZxAarsipqrWupgYFkSuYgK1KxHFc815xkOsc0z5gqMk0grwzmZZ3TGbre527c8DUaH0RnvTJtK3szjF5QyDgDXnASrbC3Kjd470wtNs520m0FYLEjKBoRCYodQbEnGG-uDvFj1Rn9d_GLLBpu9wYTn_y2xgmvrOmV0dYZFYQe7D_xPzsqgOw</recordid><startdate>202501</startdate><enddate>202501</enddate><creator>Wagner, Julian P.</creator><creator>Sauvé, Véronique</creator><creator>Saran, Anshu</creator><creator>Gehring, Kalle</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6500-1184</orcidid><orcidid>https://orcid.org/0009-0008-8905-1504</orcidid><orcidid>https://orcid.org/0000-0002-5981-4573</orcidid><orcidid>https://orcid.org/0000-0002-1232-4825</orcidid></search><sort><creationdate>202501</creationdate><title>Structural basis for the pathogenicity of parkin catalytic domain mutants</title><author>Wagner, Julian P. ; Sauvé, Véronique ; Saran, Anshu ; Gehring, Kalle</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1503-c91735a0e0c9b8fddfad151a5ca71ab2b570b67d624d703745c84d217be069f73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2025</creationdate><topic>AlphaFold</topic><topic>E3 ubiquitin ligase</topic><topic>parkin</topic><topic>PRKN</topic><topic>structural biology</topic><topic>ubiquitin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wagner, Julian P.</creatorcontrib><creatorcontrib>Sauvé, Véronique</creatorcontrib><creatorcontrib>Saran, Anshu</creatorcontrib><creatorcontrib>Gehring, Kalle</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of biological chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wagner, Julian P.</au><au>Sauvé, Véronique</au><au>Saran, Anshu</au><au>Gehring, Kalle</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Structural basis for the pathogenicity of parkin catalytic domain mutants</atitle><jtitle>The Journal of biological chemistry</jtitle><addtitle>J Biol Chem</addtitle><date>2025-01</date><risdate>2025</risdate><volume>301</volume><issue>1</issue><spage>108051</spage><pages>108051-</pages><artnum>108051</artnum><issn>0021-9258</issn><issn>1083-351X</issn><eissn>1083-351X</eissn><abstract>Mutations in the E3 ubiquitin ligase parkin cause a familial form of Parkinson’s disease. Parkin and the mitochondrial kinase PTEN-induced kinase 1 assure quality control of mitochondria through selective autophagy of mitochondria (mitophagy). Whereas numerous parkin mutations have been functionally and structurally characterized, several Parkinson’s disease mutations found in the catalytic Rcat domain of parkin remain poorly understood. Here, we characterize two pathogenic Rcat mutants, T415N and P437L. We demonstrate that both mutants exhibit impaired activity using autoubiquitination and ubiquitin vinyl sulfone assays. We determine the minimal ubiquitin-binding segment and show that both mutants display impaired binding of ubiquitin charged on the E2 enzyme. Finally, we use AlphaFold 3 to predict a model of the phospho-parkin:phospho-ubiquitin:ubiquitin-charged E2 complex. The model shows the repressor element of parkin and the N-terminal residues of the catalytic domain form a helix to position ubiquitin for transfer from the E2 to parkin. Our results rationalize the pathogenicity of the parkin mutations and deepen our understanding of the active parkin:E2∼Ub complex.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>39631693</pmid><doi>10.1016/j.jbc.2024.108051</doi><orcidid>https://orcid.org/0000-0001-6500-1184</orcidid><orcidid>https://orcid.org/0009-0008-8905-1504</orcidid><orcidid>https://orcid.org/0000-0002-5981-4573</orcidid><orcidid>https://orcid.org/0000-0002-1232-4825</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0021-9258
ispartof The Journal of biological chemistry, 2025-01, Vol.301 (1), p.108051, Article 108051
issn 0021-9258
1083-351X
1083-351X
language eng
recordid cdi_proquest_miscellaneous_3146516862
source DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection
subjects AlphaFold
E3 ubiquitin ligase
parkin
PRKN
structural biology
ubiquitin
title Structural basis for the pathogenicity of parkin catalytic domain mutants
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T02%3A50%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Structural%20basis%20for%20the%20pathogenicity%20of%20parkin%20catalytic%20domain%20mutants&rft.jtitle=The%20Journal%20of%20biological%20chemistry&rft.au=Wagner,%20Julian%20P.&rft.date=2025-01&rft.volume=301&rft.issue=1&rft.spage=108051&rft.pages=108051-&rft.artnum=108051&rft.issn=0021-9258&rft.eissn=1083-351X&rft_id=info:doi/10.1016/j.jbc.2024.108051&rft_dat=%3Cproquest_cross%3E3146516862%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3146516862&rft_id=info:pmid/39631693&rft_els_id=S0021925824025535&rfr_iscdi=true